Tuomas Tammela, M.D., Ph.D.
Memorial Sloan-Kettering Cancer Center
Interception of Incipient and Quiescent Kras-mutant Lung Epithelial Cells
Lung Cancer Discovery Award
Lung adenocarcinoma (LUAD), the most common lung cancer subtype, is commonly driven by mutations in the Kras gene. These mutations are detected in approximately 30 percent of LUAD tumors, and effective therapies against them are lacking. We will test whether inhibitors that target mutant Kras, soon entering clinical trials, can intercept early LUAD tumor growths in the mouse lung. We propose to use sophisticated lung cancer models to discover new ways of intercepting lung cancer at its earliest stages, much before it becomes a clinically detectable disease. Such approaches could be developed into effective means of preventing lung cancer.
Sign up for the latest lung health news sent right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.